Drug Trial Radar · NCT06812988
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
Last checked: Nov 19, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 28, 2025
Primary completion
Apr 29, 2027
Study completion Apr 29, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.
Conditions
- Type 1 Diabetes Mellitus
Interventions
BrivekimigDrug
Pharmaceutical form: Solution Route of administration: Subcutaneous injection
PlaceboDrug
Pharmaceutical form: Solution Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentrationTime frame: From Baseline to Week 26
Locations
24 sites in 8 countries. Site status is shown where the registry gives one.
Atlanta Diabetes Associates- Site Number : 8400006
Atlanta, Georgia
IACT Health - Columbus - Talbotton Road- Site Number : 8400012
Columbus, Georgia
Profound Research - MHP - TriAtria- Site Number : 8400015
Farmington Hills, Michigan
Tekton Research - McKinney- Site Number : 8400017
McKinney, Texas
Advanced Research Institute - Odgen- Site Number : 8400007
Ogden, Utah
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Argentina
Investigational Site Number : 0320003
Salta, Argentina
Investigational Site Number : 0360003
Saint Leonards, New South Wales, Australia
Investigational Site Number : 0360002
Brisbane, Queensland, Australia
Investigational Site Number : 0360001
Parkville, Victoria, Australia
Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760002
São Paulo, Brazil
Centro de Diabetes Curitiba- Site Number : 0760005
Curitiba, Paraná, Brazil
Investigational Site Number : 1240006
Surrey, British Columbia, Canada
Investigational Site Number : 1240001
Vancouver, British Columbia, Canada
Investigational Site Number : 1520004
Concepción, Biobio, Chile
Investigational Site Number : 1520003
Providencia, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 3760001
Jerusalem, Israel
Investigational Site Number : 3760003
Kefar Sava, Israel
Investigational Site Number : 3760002
Ramat Gan, Israel
Investigational Site Number : 6820002
Riyadh, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.